TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01160978
Drug: Simvastatin 80mg
Normalized name: SIMVASTATIN 80MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
Study: NCT00601627
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00601627
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01670240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01086722
Drug: karolinska cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol
Study: NCT03824665
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group C (Control group): included patients assigned to receive 1 ml normal saline.
Study: NCT01488929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00666029
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01818921
Drug: ZGN-440 sterile diluent
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZGN-440 sterile diluent/placebo
Study: NCT01818921
Drug: 1.2 mg ZGN-440 for injectable suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg beloranib
Study: NCT01818921
Drug: 1.8 mg ZGN-440 for injectable suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg beloranib
Study: NCT03933865
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be normal saline solution given via intramuscular injection.
Study: NCT03036748
Drug: Tbl amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day
Study: NCT02215759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01816243
Drug: TTS-Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
Study: NCT02045849
Drug: GSK2140944 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg
Study: NCT02045849
Drug: GSK2140944 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg
Study: NCT00303459
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching bosentan placebo/b.i.d.
Study: NCT01088581
Drug: Adjuvant group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (5FU and cisplatin) after resection
Study: NCT01353742
Drug: Fixed dose combination (Lamivudine and Adefovir dipivoxil)
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg/10mg capsule
Study: NCT00393874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
Study: NCT01889979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of a sterile solution was applied in the forearm SC (single dose).
Study: NCT02139319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01633853
Drug: 1,25(OH)2 Vit D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).
Study: NCT00897260
Drug: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~* Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~* Fludarabine dose adjustment:~  70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion
Study: NCT00772668
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously per protocol.
Study: NCT01661621
Drug: Detrusitol 4 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1
Study: NCT02071407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01610765
Drug: Novel Antiviral Drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 oral doses of a Novel Antiviral Drug: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
Study: NCT01610765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 oral doses of placebo matching the a Novel Antiviral Drug assigned dose: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
Study: NCT01380782
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BID oral for 28 day cycle
Study: NCT02402660
Drug: ALK-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily, oral administration for 24 months
Study: NCT02402660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily, oral administration for 24 months
Study: NCT00622986
Drug: an extract of Cimicifuga Foetida L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
Study: NCT00622986
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will be given placebo of 2 tablets each day for 3 months.
Study: NCT02611154
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
Study: NCT03676946
Drug: ZKAB001 5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg/kg/times bi-week IV administration of ZKAB001
Study: NCT03676946
Drug: ZKAB001 10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg/times bi-week IV administration of ZKAB001
Study: NCT03676946
Drug: ZKAB001 15mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/kg/times bi-week IV administration of ZKAB001
Study: NCT03261167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection will contain sodium chloride (0.9 mg).
Study: NCT03600363
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebos as a maintenance therapy
Study: NCT00527267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
Study: NCT00352599
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00352599
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
Study: NCT00352599
Drug: placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03352726
Drug: DBV712 IHRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBV712 Solution for Skin Prick Test
Study: NCT02716610
Drug: INH 139 U
Normalized name: eflornithine 139 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled human insulin
Study: NCT02716610
Drug: INH 208 U
Normalized name: testosterone 0.208 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled human insulin
Study: NCT01659320
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 100 mg twice daily for 8 weeks
Study: NCT04035317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
Study: NCT01773408
Drug: RO5503781 SDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
Study: NCT02251392
Drug: Urea cream based
Normalized name: urea Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care
Study: NCT04018911
Drug: Hearing Aid with NR_4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. This experimental condition combines standard NR and novel NR principle to result in different degrees of noise suppression and good speech quality.
Study: NCT00917449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo BID for 18 months
Study: NCT02921971
Drug: SAR156597
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous
Study: NCT02921971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous
Study: NCT00077857
Drug: capecitabine (Xeloda®)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
Study: NCT04736433
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor dispensing claim is used as the reference
Study: NCT02953535
Drug: Magicbuvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 400 mg sofosbuvir
Study: NCT00493870
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
Study: NCT00493870
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV over 15-30 minutes on Day 1.
Study: NCT03004118
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 week oral intake (daily)
Study: NCT03004118
Drug: Ursochol oral tablet
Normalized name: ursodiol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 week oral intake (daily) (dose of 10.5mg/kg/day)
Study: NCT05655338
Drug: systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03697187
Drug: rhC1INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human C1 inhibitor
Study: NCT02695472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered
Study: NCT00763139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: By mouth once a day for 8 weeks
Study: NCT01256437
Drug: Threolone ointment
Normalized name: Threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ointment once daily for 1 month
Study: NCT01256437
Drug: ointment Synthomycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ointment once daily for 1 month
Study: NCT02055716
Drug: Sulforadex
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00542555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
Study: NCT00542555
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01330238
Drug: Zoledronic acid vs. placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single infusion of zoledronic acid or placebo
Study: NCT00948870
Drug: Shugan decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decoction ,two times a day,one bag of decoction one time
Study: NCT00933049
Drug: Cotrimoxazole placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01068132
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
Study: NCT00003746
Drug: 2-chlorodeoxyadenosine (CDA) daily
Normalized name: 2-Chlorodeoxyadenosine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily administration
Study: NCT00003746
Drug: 2-chlorodeoxyadenosine weekly
Normalized name: 2-Chlorodeoxyadenosine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration
Study: NCT02698735
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.
Study: NCT02698735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.
Study: NCT00670592
Drug: HCD122
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00907400
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet
Study: NCT02449655
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
Study: NCT00958204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Pill: one oral tablet each day, for 8 weeks.
Study: NCT00958204
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine: 20 mg oral tablet each day, for 8 weeks
Study: NCT02268058
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine administration of medication for a 72 hour period
Study: NCT02268058
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: routine administration of medication for a 72 hour period
Study: NCT02449655
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
Study: NCT02076698
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: usual treatment of epilepsy Vagus nerve stimulation: maintained
Study: NCT02906618
Drug: LY3039478
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02364479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The injection method and frequency of placebo is the same as the other arms.
Study: NCT01926782
Drug: Placebo (for alirocumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Study: NCT01926782
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
Study: NCT03516760
Drug: GEM333
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion of GEM333; administered intravenously and continuously over 10 days
Study: NCT04344678
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esitalopram 20 mg tablet plus placebo tablet once daily
Study: NCT02870855
Drug: intrauterine injection of HCG
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrauterine injection of HCG berore blastocyst transfer
Study: NCT01936532
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy Patients will receive 3 cycles of induction therapy with MLN9708 (4 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22 of a 28-day cycle.~Consolidation therapy~* Early consolidation (consolidation part 1) will comprise 2 cycles of MRD identical to induction therapy.~* Late consolidation (consolidation part 2) will consist in 6 additional cycles of MLN9708 (4 mg on Days 1, 8 and 15) plus lenalidomide (25 mg on Days 1 through 21) of a 28-day cycle.~Maintenance therapy MLN9708 monotherapy (4 mg/day), will be given on days 1, 8 and 15 of a 28 day cycle, during 12 months.
Study: NCT02560610
Drug: OC000459
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02560610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01246791
Drug: NPC-01
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-01, contains 1mg norethisterone and 0.02mg ethinyl estradiol will be administered orally under the fasting condition
Study: NCT00739414
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10, 15, 20 mg/m2, i.v. on day 1 and 8 of each 21 day cycle
Study: NCT04077905
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35mg/m² ivgtt on day 1
Study: NCT00689572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
Study: NCT01523990
Drug: TG-2349
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
Study: NCT04031703
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide chemotherapy (injection)
Study: NCT03828929
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
Study: NCT01286246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of placebo (sunflower oil). One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
Study: NCT01523990
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
Study: NCT01871532
Drug: Gonal-f®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00149578
Drug: Gemcitabine Oxaliplatin 5FU and Leucovorin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03115151
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.
Study: NCT03403205
Drug: ALXN1840
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1840 administered orally in 15 mg tablets
Study: NCT01622881
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours
Study: NCT03379389
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics based on individual subjects urine culture / antibiogram
Study: NCT00725075
Drug: MK-8435 (Org 25935) 4-8 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day
Study: NCT01728064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT00725075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for MK-8435 (Org 25935) administered orally BID